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Abstract
Background Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections 
and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus 
kinase inhibitors) increase risk of infections. Dupilumab (a monoclonal antibody blocking the shared receptor component 
for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic 
or oral corticosteroid-dependent asthma.
Objective The aim was to determine the impact of dupilumab on infection rates in patients with moderate-to-severe AD.
Methods This analysis pooled data from seven randomized, placebo-controlled dupilumab trials in adults with moderate-
to-severe AD. Exposure-adjusted analyses assessed infection rates.
Results Of 2932 patients, 1091 received placebo, 1095 dupilumab 300 mg weekly, and 746 dupilumab 300 mg every 
2 weeks. Treatment groups had similar infection rates overall per 100 patient-years (placebo, 155; dupilumab weekly, 150; 
dupilumab every 2 weeks, 156; dupilumab combined, 152), and similar non-skin infection rates. Serious/severe infections 
were reduced with dupilumab (risk ratio 0.43; p < 0.05), as were bacterial and other non-herpetic skin infections (risk ratio 
0.44; p < 0.001). Although herpesviral infection rates overall were slightly higher with dupilumab than placebo, clinically 
important herpesviral infections (eczema herpeticum, herpes zoster) were less common with dupilumab (risk ratio 0.31; 
p < 0.01). Systemic anti-infective medication use was lower with dupilumab.
Conclusions Dupilumab is associated with reduced risk of serious/severe infections and non-herpetic skin infections and 
does not increase overall infection rates versus placebo in patients with moderate-to-severe AD.
ClinicalTrials.gov Identifiers NCT01548404, NCT02210780, NCT01859988, NCT02277743, NCT02277769, NCT02260986, 
and NCT02755649.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 7-019-00445 -7) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Atopic dermatitis (AD) is a chronic pruritic inflammatory 
skin disease characterized by skin barrier dysfunction, 
including imbalance of the skin microbiome, and immune 
dysregulation primarily skewed toward type 2 activity [1, 2]. 
Reduced expression of antimicrobial peptides and alterations 
in the skin microbiome, including Staphylococcus aureus 
colonization, contribute to AD pathobiology [3–5].
Patients with AD are at increased risk of serious bacterial 
skin infections and viral skin infections, including eczema 
herpeticum, eczema vaccinatum, and eczema coxsackium 
[5–17] and, compared with the general population, are at 
increased risk of serious extracutaneous and systemic infec-
tions [17–19].
Dupilumab, a fully human monoclonal antibody derived 
by proprietary technologies [20, 21], blocks the shared 
receptor component for interleukin-4 (IL-4) and IL-13, 
thus inhibiting signaling of both IL-4 and IL-13. Dupilumab 
is approved for subcutaneous (SC) administration at 
300 mg every 2 weeks (q2w) for the treatment of patients 
12 years and older in the USA with moderate-to-severe AD 
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Key Points 
We conducted a comprehensive analysis of pooled 
data from seven randomized, double-blinded, placebo-
controlled clinical trials of dupilumab (with or without 
concomitant topical corticosteroids) in adults with atopic 
dermatitis.
Dupilumab treatment does not increase infection risk 
overall and is associated with lower rates of serious or 
severe infections and lower rates of non-herpetic skin 
infections, compared with placebo.
Rates of herpesviral infections are slightly higher with 
dupilumab, mostly those due to oral herpes, but clini-
cally important herpesviral infections, such as herpes 
zoster and eczema herpeticum, are lower with dupilumab 
than placebo.
Because pooling data from multiple clinical trials 
increases the likelihood of identifying and confirming 
signals from individual studies, we conducted a compre-
hensive analysis of pooled data from randomized, placebo-
controlled, double-blinded, phase II and phase III clinical 
trials with treatment periods of 12–52 weeks to further 
evaluate the incidence of infections in studies of dupilumab 
in patients with AD. The objective of this pooled analysis 
was to assess infection rates for two regimens of dupilumab 
(SC 300 mg weekly [qw] or 300 mg q2w), compared with 
placebo, in adult patients with moderate-to-severe AD.
2  Methods
2.1  Studies
This pooled analysis included data from seven phase II 
and phase III randomized, placebo-controlled, double-
blinded studies of dupilumab in adults with moderate-to-
severe AD (R668-AD-1117, LIBERTY AD EVALUATE, 
R668-AD-1021, LIBERTY AD SOLO 1, LIBERTY AD 
SOLO 2, LIBERTY AD CHRONOS, and LIBERTY AD 
CAFÉ) [47–52]. Detailed study designs are provided in the 
respective publications and are summarized in Table E1 in 
the Electronic Supplementary Material (ESM).
The analyses included all patients who received at least 
one dose of study drug (SC dupilumab 300 mg qw, 300 mg 
q2w, or placebo). Patients were categorized in treatment 
groups based on the treatment received (safety analysis set).
2.2  Endpoints
The endpoints used in this study are described in Table E2 in 
the ESM and include infections overall, infections leading to 
permanent discontinuation of study drug, serious or severe 
infections, non-herpetic skin infections, non-skin infections, 
and herpesviral infections. The definitions of the endpoints 
are based on reports of treatment-emergent adverse events 
(TEAEs) made during the treatment period of the clinical 
trials and are described according to the system organ class, 
high-level term (HLT), and preferred term (PT) of the ver-
sion of the Medical Dictionary for Regulatory Activities 
(MedDRA) used in the respective study.
2.3  Assessments and Statistical Analyses
Events per 100 patient-years (PY) and patients with at least 
one event per 100 PY were assessed during the study treat-
ment period.
Exposure-adjusted rates were used to compare dupilumab 
treatment (300  mg qw, 300  mg q2w, and combined 
qw + q2w) with placebo, and p values were obtained from a 
inadequately controlled with topical prescription therapies 
or when those therapies are not advisable [22], for the treat-
ment of adult AD patients not adequately controlled with 
existing therapies in Japan [23], and for use in adults with 
inadequately controlled, moderate-to-severe AD who are 
candidates for systemic therapy in the European Union 
[24]. Dupilumab is also approved by the US Food and Drug 
Administration [22] as an add-on maintenance treatment in 
patients with moderate-to-severe asthma aged ≥ 12 years 
with an eosinophilic phenotype or with oral corticosteroid-
dependent asthma, regardless of eosinophilic phenotype 
[25–27]. In addition, dupilumab treatment has significantly 
improved signs and symptoms and had an overall favorable 
safety profile in clinical trials in other type 2 immune dis-
eases, including chronic rhinosinusitis with nasal polyposis 
(CRSwNP), and eosinophilic esophagitis, thus demonstrat-
ing the importance of IL-4 and IL-13 as drivers of multiple 
type 2 atopic/allergic diseases [28, 29].
Immunomodulatory agents, such as anti-tumor necro-
sis factor (anti-TNF) agents, anti-IL-23, anti-IL-17, and 
Janus kinase (JAK) inhibitors, increase the risk of infec-
tions [30–46]. However, in clinical trials with dupilumab, 
there was no evidence of an increase in overall infection 
rates, nor was there evidence of increased risk of serious 
or opportunistic infections in dupilumab-treated patients 
[25–29, 47–53]. Moreover, in clinical trials of dupilumab 
in patients with moderate-to-severe AD, dupilumab-treated 
patients have shown trends toward lower rates of bacterial 
and other non-herpetic skin infections and lower rates of the 
clinically important herpesviral infections eczema herpeti-
cum and herpes zoster, but slightly higher rates of herpes 
simplex viral infections (i.e., non-eczema herpeticum or 
herpes zoster) compared with placebo [47–52].
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time-to-event exponential regression model with treatment 
as the only covariate. There was no apparent dose–response 
relation for infections with the dupilumab qw and q2w regi-
mens, so statistical comparison of dupilumab versus placebo 
was carried out using the dupilumab qw and q2w groups 
combined.
In addition, for the overall endpoints, the differences 
between dupilumab and placebo were described separately 
for the monotherapy studies (R668-AD-1117, EVALU-
ATE, R668-AD-1021, SOLO 1, and SOLO 2) and studies of 
dupilumab that required concomitant topical corticosteroids 
(TCS) (CHRONOS and CAFÉ) by using exposure-adjusted 
rates. Unless otherwise indicated, given the pooling of data 
from both monotherapy and concomitant therapy studies in 
the overall analyses, the terms “dupilumab” and “placebo” 
refer to the study treatments. Finally, numbers (percentage) 
of patients with 0, 1, 2, 3, 4, and > 4 events of infections 
overall, serious or severe infections, non-herpetic skin infec-
tions, and herpesviral infections are provided using descrip-
tive statistics.
3  Results
3.1  Patients
Data from 2932 patients were included in this analysis, of 
whom 1091 received placebo, 1095 dupilumab 300 mg qw, 
and 746 dupilumab 300 mg q2w.
3.2  Exposure‑Adjusted Infection Rates
There were no significant differences between treatment 
groups in overall infection rates calculated either as the 
number of patients with at least one infection per 100 PY 
(Table 1) or in the number of events per 100 PY (Table E3 
in the ESM). Rates of events per 100 PY followed a trend 
similar to those seen for patients with at least one event 
per 100 PY. Approximately 129 patients per 100 PY in the 
placebo group had at least one infection, compared with 
approximately 126, 134, and 129 patients per 100 PY in the 
dupilumab 300 mg qw, 300 mg q2w, and combined groups, 
respectively. Similarly, there were approximately 155 infec-
tions per 100 PY in the placebo group and 150, 156, and 
152 infections per 100 PY in the dupilumab 300 mg qw, 
300 mg q2w, and combined groups, respectively. There 
were no apparent differences in infection rates between the 
dupilumab regimens.
Overall, a higher proportion of patients in the placebo 
group than in the dupilumab group discontinued for any 
reason (18.3% vs. 8.0%, placebo vs. dupilumab com-
bined; 42.59 vs. 18.48 patients per 100 PY, respectively; 
p < 0.0001). Very few patients permanently discontinued 
study treatment because of infections (five patients in the 
placebo group and three in the dupilumab groups combined), 
and there were no significant differences in discontinuation 
rates between treatment groups (Table 1 and Fig. 1a; and 
Table E3 in the ESM). Infections that led to treatment dis-
continuation in the placebo group were, by MedDRA PT, 
cytomegalovirus infection, infected dermatitis, eczema her-
peticum, bacterial endocarditis, molluscum contagiosum, 
sepsis, and septic embolus (one case each; one patient who 
discontinued had three infectious TEAEs [bacterial endo-
carditis, sepsis, and septic embolus]). Infections that led to 
treatment discontinuation in the dupilumab groups were 
conjunctivitis, eczema impetiginous, and folliculitis (one 
case each).
Serious or severe infections were uncommon, but sig-
nificantly less common in the dupilumab groups than in 
placebo, when assessed either as the number of patients per 
100 PY (risk ratio [RR] 0.43, p = 0.02, dupilumab combined 
vs. placebo; Table 1 and Fig. 1b) or as the number of events 
per 100 PY (RR 0.38, p = 0.004, dupilumab combined vs. 
placebo; Table E3 in the ESM).
Skin infections (non-herpetic) were significantly less 
common in the dupilumab groups than in the placebo group, 
whether assessed as MedDRA HLT (number of patients per 
100 PY: RR 0.44, p < 0.001, dupilumab combined vs. pla-
cebo) or as adjudicated skin infections (number of patients 
per 100 PY: RR 0.55, p < 0.001, dupilumab combined vs. 
placebo; Fig. 2a and Table 1; and Table E3 in the ESM). One 
patient each in the placebo and dupilumab qw groups had an 
ectoparasitic infection (acarodermatitis).
Non-skin infections (i.e., excluding infections assessed 
as skin-structure or soft-tissue infections by MedDRA HLT) 
occurred at similar exposure-adjusted rates in the placebo 
and dupilumab groups (Table 1; and Table E3 in the ESM). 
Common non-skin infections (MedDRA PTs) that were 
more frequent in the dupilumab groups combined than in 
the placebo group were nasopharyngitis, upper respiratory 
tract infection, conjunctivitis, oral herpes, and bacterial 
conjunctivitis; those that were more frequent in the placebo 
group than in the dupilumab groups combined included uri-
nary tract infection, influenza, gastroenteritis, viral upper 
respiratory tract infection, and pharyngitis (Table 2). Event 
rates (Table E4 in the ESM) were broadly similar to patient 
incidence rates (Table 2).
Systemic or invasive infections were uncommon; of note, 
one patient in the dupilumab q2w group had, by MedDRA 
PT, bacterial sepsis, two patients in the placebo group had 
sepsis (including one who also had bacterial endocarditis 
and septic embolus, which led to treatment discontinuation, 
as noted above), and one patient in the placebo group had 
a moderate cytomegalovirus infection that led to treatment 
discontinuation, as noted above. There were no cases of 
endoparasitic (e.g., helminthic) infections.
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Overall rates of herpesviral infections did not differ sig-
nificantly between placebo and dupilumab groups when 
assessed as the number of patients with at least one event 
per 100 PY, but when assessed as the number of events per 
100 PY, they were slightly more common in the dupilumab 
q2w group and the dupilumab groups combined than in the 
placebo group (Table 1; and Table E3 in the ESM). The clin-
ically important herpesviral infections eczema herpeticum 
Table 1  Exposure-adjusted numbers of patients with treatment-emergent infections during the study treatment period
At each level of patient summarization, a patient is counted once if the patient reported ≥ 1 event. TEAEs included in the analysis were those that 
occurred during the study treatment period
CI confidence interval, HLT MedDRA high-level term, MedDRA Medical Dictionary for Regulatory Activities, nP number of patients with ≥ 1 
event, nP/100 PY number of patients with ≥ 1 event per 100 PY, PY patient-years, q2w every 2 weeks, qw weekly, TEAE treatment-emergent 
adverse event
a p values are from a time-to-event exponential regression model with treatment as the only covariate
b Infections that led to treatment discontinuation in the placebo group were cytomegalovirus infection, infected dermatitis, eczema herpeticum, 
bacterial endocarditis, molluscum contagiosum, sepsis, and septic embolus (1 case each; 1 patient who discontinued had 3 infectious TEAEs 
[bacterial endocarditis, sepsis, and septic embolus]). Infections that led to treatment discontinuation in the dupilumab group were conjunctivitis, 
eczema impetiginous, and folliculitis (1 case each)
c MedDRA HLT
d Excluding herpesviral infections; data not available for R668-AD-1117
e Includes all infections other than those listed in the MedDRA HLT skin structures and soft tissue infections
Patients with ≥ 1 event, nP (nP/100 PY) Comparison with placebo, risk ratio (95% CI)  
p  valuea
Placebo 
(n = 1091)
Dupilumab 
300 mg qw 
(n = 1095)
Dupilumab 
300 mg q2w 
(n = 746)
Dupilumab 
combined 
(n = 1841)
Dupilumab 
300 mg qw
Dupilumab 
300 mg q2w
Dupilumab 
combined
Overall 453 (129.317) 452 (126.486) 287 (133.580) 739 (129.149) 0.98 (0.86, 
1.11)
0.74
1.03 (0.89, 
1.20)
0.67
1.00 (0.89, 1.12)
0.98
Infections leading 
to treatment 
 discontinuationb
5 (0.986) 2 (0.382) 1 (0.340) 3 (0.367) 0.39 (0.08, 
2.00)
0.26
0.35 (0.04, 
2.95)
0.33
0.37 (0.09, 1.56)
0.18
Serious or severe 
infections
20 (3.978) 7 (1.340) 7 (2.393) 14 (1.718) 0.34 (0.14, 
0.80)
0.01
0.60 (0.25, 
1.42)
0.25
0.43 (0.22, 0.85)
0.02
Non-herpetic skin infections
 Skin structures 
and soft tissue 
 infectionsc
55 (11.255) 23 (4.455) 17 (5.867) 40 (4.963) 0.40 (0.24, 
0.64)
< 0.001
0.52 (0.30, 
0.90)
0.02
0.44 (0.29, 0.66)
< 0.001
 Adjudicated skin 
 infectionsd
122 (26.563) 69 (13.881) 44 (15.672) 113 (14.527) 0.52 (0.39, 
0.70)
< 0.001
0.59 (0.42, 
0.83)
0.003
0.55 (0.42, 0.71)
< 0.001
Non-skin 
 infectionse
424 (117.862) 443 (122.416) 281 (129.691) 724 (125.141) 1.04 (0.91, 
1.19)
0.58
1.10 (0.95, 
1.28)
0.21
1.06 (0.94, 1.20)
0.33
Herpesviral infections
 Total 51 (10.379) 57 (11.262) 43 (15.243) 100 (12.687) 1.09 (0.74, 
1.58)
0.67
1.47 (0.98, 
2.20)
0.06
1.22 (0.87, 1.71)
0.24
 Clinically impor-
tant (eczema 
herpeticum, 
herpes zoster)
18 (3.590) 3 (0.573) 6 (2.054) 9 (1.104) 0.16 (0.05, 
0.54)
0.003
0.57 (0.23, 
1.44)
0.24
0.31 (0.14, 0.68)
0.004
 Eczema herpe-
ticum
12 (2.380) 2 (0.382) 4 (1.368) 6 (0.735) 0.16 (0.04, 
0.72)
0.02
0.57 (0.19, 
1.78)
0.34
0.31 (0.12, 0.82)
0.02
 Herpes zoster 7 (1.384) 1 (0.191) 2 (0.681) 3 (0.367) 0.14 (0.02, 
1.12)
0.06
0.49 (0.10, 
2.37)
0.38
0.27 (0.07, 1.03)
0.055
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and herpes zoster were both uncommon; eczema herpeticum 
was significantly more common in the placebo group than in 
the dupilumab qw or dupilumab combined groups, whether 
assessed as patients per 100 PY or events per 100 PY 
(Table 1; and Table E3 in the ESM). The incidence of herpes 
zoster infection was numerically higher in the placebo group 
compared with the dupilumab groups (Table 1; and Table E3 
in the ESM). However, the combined rate of the clinically 
important herpesviral infections eczema herpeticum and 
herpes zoster was significantly higher in the placebo group 
than in the dupilumab qw group (RR 0.16, p = 0.003) or the 
dupilumab groups combined (RR 0.31, p = 0.004; Table 1; 
and Table E3 in the ESM).
The overall patterns of infection in studies in 
which dupilumab was administered as monotherapy 
(R668-AD-1117, EVALUATE, R668-AD-1021, SOLO 1, 
and SOLO 2) or with concomitant TCS (CHRONOS and 
CAFÉ) were similar to those seen in the full analysis of 
Fig. 1  Exposure-adjusted  
numbers of patients with 
treatment-emergent infections 
during the study treatment  
period. a Infections leading to 
treatment discontinuation.  
b Serious or severe infections. 
At each level of patient sum-
marization, a patient is counted 
once if the patient reported ≥ 1 
event. Treatment-emergent 
adverse events included in 
the analysis were those that 
occurred during the study treat-
ment period. p values are from 
a time-to-event exponential 
regression model with treatment 
as the only covariate. RRs for 
significant p values are shown 
in bold. CI confidence interval, 
nP number of patients with ≥ 1 
event, PY patient-years, q2w 
every 2 weeks, qw weekly, RR 
risk ratio
0.99
0.38 0.34 0.37
0
1
2
3
4
5
Placebo Dupilumab 300 mg qw Dupilumab 300 mg q2w Dupilumab combined
RR 0.39
(95% CI
0.08, 2.00);
p = 0.26
RR 0.35
(95% CI
0.04, 2.95);
p = 0.33
RR 0.37
(95% CI
0.09, 1.56);
p = 0.18
3.98
1.34
2.39
1.72
RR 0.34
(95% CI
0.14, 0.80);
p = 0.01
RR 0.60
(95% CI
0.25, 1.42);
p = 0.25 
RR 0.43
(95% CI
0.22, 0.85);
p = 0.02 
0
1
2
3
4
5
Placebo Dupilumab 300 mg qw Dupilumab 300 mg q2w Dupilumab combined
a
b
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pooled data: in both of these groups of studies there 
were similar rates of infections overall in the placebo and 
dupilumab groups, and higher rates of serious or severe 
infections, non-herpetic skin infections, and clinically 
important herpesviral infections (eczema herpeticum or 
herpes zoster) in the placebo groups than in the dupilumab 
groups (Tables E5 and E6 in the ESM). Skin infections 
were reported at higher rates in all treatment groups in the 
monotherapy studies than in the concomitant TCS studies 
(Fig. 2b).
3.3  Patients with Multiple Infections
There were no apparent differences between treatment 
groups in the percentages of patients with multiple (≥ 2 
vs. 0 or 1) infections overall, skin infections, or herpesviral 
infections (Table E7 in the ESM). Multiple total infections 
were reported in similarly small proportions of patients in 
the placebo and dupilumab groups. One patient had two seri-
ous or severe infections and another had three such events; 
both patients were in the placebo group. More patients in 
Fig. 2  Exposure-adjusted  
numbers of patients with 
treatment-emergent skin  
infections (non-herpetic) during 
the study treatment period.  
a Skin infections by HLT and 
adjudicated skin infections.  
b Adjudicated skin infections in 
monotherapy studies and studies 
with concomitant TCS. At each 
level of patient summarization, 
a patient is counted once if 
the patient reported ≥ 1 event. 
Treatment-emergent adverse 
events included in the analysis 
were those that occurred during 
the study treatment period.  
p values are from a time-to-
event exponential regression 
model with treatment as the 
only covariate. RRs for sig-
nificant p values are shown in 
bold. CI confidence interval, 
HLT MedDRA high-level term, 
MedDRA Medical Dictionary 
for Regulatory Activities, nP 
number of patients with ≥ 1 
event, PY patient-years, q2w 
every 2 weeks, qw weekly, RR 
risk ratio, TCS topical corticos-
teroids. aMedDRA HLT
11.26
26.56
4.46
13.88
5.87
15.67
4.96
14.53
Placebo Dupilumab 300 mg qw Dupilumab 300 mg q2w Dupilumab combined
RR 0.40
(95% CI
0.24,
0.64);
p < 0.001
RR 0.52
(95% CI
0.30,
0.90);
p = 0.02
RR 0.44
(95% CI
0.29,
0.66);
p < 0.001
RR 0.52
(95% CI
0.39,
0.70);
p < 0.001
RR 0.59
(95% CI
0.42,
0.83);
p = 0.003
RR 0.55
(95% CI
0.42,
0.71);
p < 0.001
10
0
15
20
25
30
ssa
5
31.14
23.53
20.52
9.77
19.40
11.10
20.02
10.16
Studies with concomitant TCS
RR 0.66
(95% CI
0.44,
0.99);
p = 0.04
RR 0.62
(95% CI
0.40,
0.97);
p = 0.04
RR 0.64
(95% CI
0.45,
0.91);
p = 0.01
RR 0.42
(95% CI
0.27,
0.64);
p < 0.001
RR 0.47
(95% CI
0.26,
0.84);
p = 0.01
RR 0.43
(95% CI
0.29,
0.63);
p < 0.001
Placebo Dupilumab 300 mg qw Dupilumab 300 mg q2w Dupilumab combined
10
0
15
20
25
35
Monotherapy studies
5
30
a
b
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the placebo group than in the dupilumab groups had two 
or more skin infections (whether assessed as the HLT skin 
structures and soft tissue infections or as adjudicated skin 
infections). Multiple herpesviral infections were reported in 
very small proportions of patients in the placebo group and 
in the dupilumab groups combined.
3.4  Anti‑Infective Medications
Concomitant systemic anti-infective medications were used 
significantly less by patients in the dupilumab groups than in 
the placebo group (RR 0.78, p = 0.002, dupilumab combined 
vs. placebo; Fig. 3).
4  Discussion
In this pooled analysis, dupilumab- and placebo-treated 
patients did not significantly differ in their rates of over-
all infections or discontinuation due to infections, whereas 
serious or severe infections, skin infections, and clinically 
important herpesviral infections (eczema herpeticum or her-
pes zoster) occurred at lower rates in the dupilumab groups 
than in the placebo group. Fewer systemic anti-infectives 
were used in the dupilumab groups than in the placebo 
group. There were no differences in infection rates overall 
between dupilumab regimens. Pooling data from multiple 
studies increased the sample size and thereby increased the 
Table 2  Treatment-emergent infections (by MedDRA PT) by incidence rate: number of patients per 100 PY (includes any PT reported 
in > 5 patients in the placebo group, dupilumab 300 mg qw group, or dupilumab 300 mg q2w group)
At each level of patient summarization, a patient is counted once if the patient reported ≥ 1 event. TEAEs included in the analysis were those that 
occurred during the study treatment period
MedDRA Medical Dictionary for Regulatory Activities, nP number of patients with ≥ 1 event, nP/100 PY number of patients with ≥ 1 event per 
100 PY, PT MedDRA preferred term, PY patient-years, q2w every 2 weeks, qw weekly, TEAE treatment-emergent adverse event
Infection (PT) Patients with infection, nP (nP/100 PY)
Placebo (n = 1091) Dupilumab 300 mg qw 
(n = 1095)
Dupilumab 300 mg q2w 
(n = 746)
Dupilumab com-
bined (n = 1841)
Nasopharyngitis 145 (31.378) 155 (32.835) 102 (38.178) 257 (34.766)
Upper respiratory tract infection 62 (12.834) 80 (16.254) 30 (10.616) 110 (14.198)
Conjunctivitis 10 (1.975) 45 (8.732) 33 (11.445) 78 (9.705)
Oral herpes 17 (3.376) 36 (7.033) 27 (9.407) 63 (7.886)
Bacterial conjunctivitis 9 (1.780) 17 (3.289) 10 (3.429) 27 (3.339)
Sinusitis 16 (3.174) 23 (4.493) 4 (1.364) 27 (3.354)
Urinary tract infection 24 (4.783) 17 (3.283) 10 (3.433) 27 (3.337)
Herpes simplex 10 (1.975) 11 (2.114) 13 (4.475) 24 (2.960)
Influenza 23 (4.600) 15 (2.887) 8 (2.748) 23 (2.837)
Gastroenteritis 14 (2.788) 13 (2.499) 9 (3.085) 22 (2.709)
Viral upper respiratory tract infection 16 (3.186) 13 (2.516) 6 (2.061) 19 (2.352)
Pharyngitis 18 (3.565) 12 (2.307) 6 (2.047) 18 (2.213)
Rhinitis 8 (1.579) 13 (2.506) 5 (1.712) 18 (2.220)
Bronchitis 12 (2.373) 9 (1.725) 7 (2.394) 16 (1.965)
Cystitis 5 (0.986) 8 (1.535) 4 (1.366) 12 (1.474)
Molluscum contagiosum 3 (0.591) 9 (1.734) 2 (0.681) 11 (1.353)
Cellulitis 13 (2.578) 8 (1.537) 2 (0.683) 10 (1.230)
Respiratory tract infection 5 (0.985) 7 (1.342) 1 (0.340) 8 (0.981)
Tonsillitis 3 (0.591) 6 (1.149) 2 (0.681) 8 (0.981)
Gastroenteritis viral 8 (1.577) 3 (0.574) 4 (1.365) 7 (0.858)
Conjunctivitis viral 2 (0.393) 1 (0.191) 5 (1.708) 6 (0.735)
Eczema herpeticum 12 (2.380) 2 (0.382) 4 (1.368) 6 (0.735)
Furuncle 8 (1.582) 1 (0.191) 5 (1.715) 6 (0.736)
Staphylococcal skin infection 7 (1.382) 3 (0.574) 3 (1.025) 6 (0.736)
Otitis externa 10 (1.980) 3 (0.574) 2 (0.681) 5 (0.613)
Herpes zoster 7 (1.384) 1 (0.191) 2 (0.681) 3 (0.367)
Bacterial skin infection 12 (2.374) 2 (0.383) 0 2 (0.245)
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precision of the analysis, thus providing the opportunity 
to confirm or refute trends noted in individual studies and 
enhancing the ability to detect rare events. Outcomes of this 
pooled data analysis are consistent with those of the individ-
ual studies, and no new safety signals were detected [47–52].
In this pooled data analysis, dupilumab, compared with 
placebo, reduces rates of skin infections, consistent with 
the individual studies [47–52]; differences between the 
pooled groups were nominally statistically significant. The 
aggregate rate of skin infections in pooled placebo groups 
in this analysis are consistent with placebo-group rates in 
clinical trials of other therapies in similar populations [54], 
reflecting the considerable burden of skin infections in mod-
erate-to-severe AD. Skin infections are common in patients 
with AD and more so in patients with severe disease [4, 
5, 11–13, 54–56]. Several aspects of the pathobiology of 
AD may increase patients’ susceptibility to skin infections, 
including skin barrier dysfunction, skin damage associated 
Fig. 3  Systemic anti-infective 
medication use. a Number of 
patients with ≥ 1 use of systemic 
anti-infective medication per 
100 PY. b Systemic anti-
infective medication use by 
number of events per 100 PY. 
RRs for significant p values are 
shown in bold. CI confidence 
interval, nE number of events, 
nP number of patients with ≥ 1 
event, PY patient-years, q2w 
every 2 weeks, qw weekly, RR 
risk ratio
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with scratching, alterations in the skin microbiome, and a 
reduced expression of antimicrobial peptides [4, 11, 55, 56]. 
Impairment of the epidermal barrier function results in part 
from the overexpression of type 2 cytokines and imbalance 
of the skin microbiome [56]. Therefore, the lower incidence 
of skin infections in dupilumab-treated patients compared 
with placebo-treated patients may be a result of several 
mechanisms, including dupilumab-mediated improvement of 
skin barrier function (either indirectly through inhibition of 
type 2 cytokines or directly through a reduction in mechani-
cal damage to the skin caused by scratching) and favorable 
changes to the microbiome. Indeed, dupilumab reduces the 
abundance of S. aureus and increases microbial diversity 
on lesional and non-lesional skin in patients with AD [57].
Rates of serious or severe infections were significantly 
lower in the dupilumab groups combined than in the placebo 
group, and there was no evidence of an increase in risk of 
opportunistic infections with dupilumab. Serious and severe 
infections were grouped on the basis that these categories 
probably overlap. Overall, rates of serious or severe infection 
were low in this analysis, especially compared with rates 
reported with immunosuppressive medications [58–61]. 
The risks of extracutaneous and invasive infections can be 
increased by systemic medications with a broad immuno-
suppressive effect, such as corticosteroids and non-steroidal 
immunosuppressants (e.g., cyclosporine, methotrexate, aza-
thioprine, mycophenolates, and JAK inhibitors), medications 
that may be used in patients with moderate-to-severe AD (or 
are in development for AD) [11, 30, 58, 60, 62, 63].
Biologic agents that target the immunologic pathways asso-
ciated with AD and other atopic diseases provide potentially 
more specific and effective therapeutic approaches than use 
of broad systemic immunosuppressants [64, 65]. However, in 
clinical experience, type 1 immunity-suppressing biologics in 
rheumatologic and dermatologic disorders are associated with 
an increased risk of infection in general, and with increased 
risks of serious extracutaneous and systemic infections such 
as tuberculosis, bacterial sepsis, opportunistic infections, and 
invasive fungal infections (e.g., histoplasmosis) [31–46, 66]. 
These biologics are mainly TNF-α and IL-17 inhibitors and 
affect type 1 immune responses important in host immunity 
[40, 41]. Indeed, some biologics used to treat psoriasis have 
boxed warnings of the risk of serious infections, and many 
biologics, including TNF-α inhibitors (e.g., adalimumab, inf-
liximab, etanercept, and certolizumab pegol), IL-17 inhibi-
tors (secukinumab and ixekizumab), and IL-12/IL-23 inhibi-
tors (ustekinumab and guselkumab), carry a requirement for 
patient testing for tuberculosis before use [31–38].
In contrast to other biologics, dupilumab targets the activ-
ity of IL-4 and IL-13, cytokines important in type 2 immune 
pathways, which are not crucial to host defense mechanisms 
against most infectious agents, except endoparasites, specifi-
cally intestinal helminths [67–70]. This analysis of pooled 
data from dupilumab studies revealed no parasitic infections 
other than one case each of ectoparasitic infection (acaroder-
matitis) in the placebo group and the dupilumab qw group; 
none of the studies included in this analysis reported tuber-
culosis infections or reactivations. Of note, dupilumab did 
not have an impact on T-cell- and B-cell-mediated (or non-T-
cell-mediated) antibody response in a clinical trial using two 
non-live vaccines (tetanus toxoid, reduced diphtheria toxoid, 
and acellular pertussis vaccine; and quadrivalent meningo-
coccal polysaccharide vaccine) [50]. Direct evidence sup-
porting the safety of administering live vaccines in patients 
treated with dupilumab is not yet available.
The overall incidence of total herpesviral infections was 
low in all groups. Herpesviral infection incidence rates overall 
were slightly higher in the dupilumab groups than in the pla-
cebo group, but the difference was small (< 1%). Oral herpes 
(herpes labialis) accounted for most of the herpesviral infec-
tions. The molecular basis of herpes simplex viral reactivation 
is poorly understood, but the external triggers are fairly well 
characterized (e.g., sun exposure, stress) [71–73]. Notably, 
the incidences of eczema herpeticum and herpes zoster were 
higher in the placebo group than in the dupilumab groups. 
The higher rate of eczema herpeticum in the placebo group 
reflects the increased risk of this clinically important and dan-
gerous herpesviral infection in patients with AD, an infection 
reported to occur in approximately 3% of patients with AD 
[14]. Patients affected by eczema herpeticum tend to have type 
2-dominant disease [6], and the smaller number of events of 
this infection in the dupilumab groups is consistent with the 
mechanism of action of dupilumab, which inhibits signaling 
of IL-4 and IL-13, key drivers of type 2 immune diseases.
There were few differences between the dupilumab 
and placebo groups in the incidences of specific types of 
infectious disease as described by PTs. One exception was 
conjunctivitis, which was more common in dupilumab-
treated patients than placebo-treated patients. However, 
the MedDRA PT “conjunctivitis” represents conjunctivi-
tis of unspecified or undetermined etiology and defaults 
to the “Infections and Infestations” system organ class in 
MedDRA. Based on feedback from investigators through 
the data query process in these clinical trials, most of the 
adverse events coded as the PT “conjunctivitis” appeared to 
be non-infectious, but otherwise of unclear etiology. Indeed, 
there were no statistically significant differences between 
the dupilumab and placebo groups in the incidences of PT-
defined conjunctivitis with specified bacterial or viral etiol-
ogy. Current data indicate that dupilumab is associated with 
an increased incidence of conjunctivitis (all etiologies and 
clinical phenotypes combined) in patients with moderate-to-
severe AD [48–52]; notably, no such increase was observed 
with dupilumab in studies of asthma [25–27] or CRSwNP 
[28], suggesting that this phenomenon is specific to the 
AD setting. As a result, adverse events of conjunctivitis of 
452 L. F. Eichenfield et al.
undetermined etiology (PT “conjunctivitis”) that were clas-
sified as infections by the default MedDRA coding pathway 
may have slightly inflated the rate of overall infections in this 
pooled analysis, mostly for dupilumab-treated patients. A 
detailed report of conjunctivitis adverse events in dupilumab 
clinical trials provides an in-depth analysis of these events 
[74].
Dupilumab monotherapy studies and studies that required 
use of concomitant TCS had similar patterns of infection 
rates overall. In contrast, rates of skin infections were higher 
in all treatment groups in the monotherapy studies than in 
the studies that required concomitant TCS use, an obser-
vation suggesting that concomitant TCS provides a benefit 
additional to that of dupilumab in preventing skin infec-
tions, perhaps through incremental additional improvement 
in overall skin condition [48–52].
Multiple infections were uncommon. The placebo and 
dupilumab groups contained similar proportions of patients 
with multiple infections overall. In contrast, the placebo 
groups had higher proportions of patients with multiple skin 
infections, a finding consistent with higher overall rates of 
skin infections in the placebo group than in the dupilumab 
groups.
Meta-analyses of infections in dupilumab clinical trials 
have reported similar outcomes [75, 76]. However, com-
pared with those meta-analyses, the present pooled analysis 
was more thorough, with full access to the clinical database 
and raw data, and thus was more robust, with more complete 
information than the previously published meta-analyses [3, 
4], which were based only on published data.
Our analysis has some limitations. Although this pooled 
analysis provides data on a large number of patients, includ-
ing a robust control group, there are also some limitations in 
this analysis, including those related to MedDRA terminol-
ogy. A higher dropout rate in the placebo group may have 
resulted in an underestimation of infection rates, because 
it limited the opportunity to observe randomly occurring 
adverse events, including infections. Exposure-adjusted 
analyses mitigate, but do not completely remove, this bias 
in favor of placebo, particularly in the analysis of recurring 
events. This analysis was limited to randomized, placebo-
controlled clinical trials, which enabled comparison of pla-
cebo- and dupilumab-treated patients, but the numbers of 
patients may still be too small to identify risks associated 
with rare events. As the population of patients treated with 
dupilumab increases over time, further data will become 
available on these risks. There were no endoparasitic infec-
tions (e.g., helminthic infections) reported in this analy-
sis; however, the studies were conducted mostly in North 
America and Europe and did not include known endemic 
regions for parasites. Type 2 immunity is a key component 
of anti-helminthic host defense [77, 78], so further data are 
needed in patients from regions endemic for these types of 
parasitic infections. The results of our infection analyses 
used pooled data from the safety analysis sets and did not 
account for the effects of rescue medication, which was used 
by considerably more patients in the placebo group than in 
the dupilumab groups. In most cases, the rescue medica-
tion was TCS, which could potentially reduce the incidence 
of skin infections by reducing inflammation or altering the 
microbiome [79]. On the other hand, TCS could exacerbate 
infections by inhibiting healing [80]. This situation reflects 
real-world treatment paradigms, in which patients may 
receive additional medications to their baseline treatment 
in case of AD exacerbation. Because few patients received 
immunosuppressants as rescue medication, we did not per-
form subgroup analyses by immunosuppressant use; such 
subgroup analyses would have had a very small sample and 
therefore could not provide much insight into any additional 
impact of rescue immunosuppressant use on infection risk.
5  Conclusions
Rates of serious or severe infections and bacterial non-
herpetic skin infections were significantly lower in the 
dupilumab groups compared with the placebo group, in this 
pooled analysis of data from phase II and phase III clini-
cal trials of dupilumab. There was no significant difference 
between dupilumab and placebo groups in overall infec-
tion rates, and overall, there were no differences in infec-
tion rates between the dupilumab regimens. The dupilumab 
groups had lower use of systemic anti-infective medica-
tions than the placebo group. Overall, herpesviral infec-
tions were more common in the dupilumab 300 mg q2w 
and dupilumab groups combined, versus the placebo group, 
but the clinically more concerning eczema herpeticum and 
herpes zoster infections were less common with dupilumab 
than with placebo. The results of this analysis support the 
safety of dupilumab for the treatment of moderate-to-severe 
AD in adults, and the larger sample provided by pooling data 
showed no new safety signals.
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